UBS AM
ZNTL icon

UBS AM’s Zentalis Pharmaceuticals ZNTL Stock Holding History

UBS AM’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-113,386
Closed -$464K – 2871
2024
Q2 		$464K Buy
113,386
+45,914
+68% +$513K ﹤0.01% 2643
2024
Q1 		$1.06M Buy
67,472
+4,296
+7% +$59.1K ﹤0.01% 1980
2023
Q4 		$957K Sell
63,176
-185,938
-75% -$2.71M ﹤0.01% 2045
2023
Q3 		$5M Buy
249,114
+20,777
+9% +$527K ﹤0.01% 1205
2023
Q2 		$3.93M Hold
228,337
– – ﹤0.01% 1344
2023
Q1 		$3.93M Sell
228,337
-11,671
-5% -$236K ﹤0.01% 1344
2022
Q4 		$4.83M Buy
240,008
+14,112
+6% +$304K ﹤0.01% 1185
2022
Q3 		$4.89M Buy
225,896
+81,401
+56% +$2.23M ﹤0.01% 1211
2022
Q2 		$4.06M Buy
144,495
+14,724
+11% +$390K ﹤0.01% 1285
2022
Q1 		$5.99M Sell
129,771
-7,813
-6% -$421K ﹤0.01% 1280
2021
Q4 		$11.6M Buy
137,584
+117,283
+578% +$9.08M ﹤0.01% 1068
2021
Q3 		$1.35M Buy
20,301
+198
+1% +$11.4K ﹤0.01% 2014
2021
Q2 		$1.07M Buy
20,103
+2,503
+14% +$134K ﹤0.01% 2169
2021
Q1 		$764K Buy
17,600
+6,100
+53% +$263K ﹤0.01% 2207
2020
Q4 		$597K Buy
+11,500
New +$519K ﹤0.01% 2233

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

UBS AM's ZNTL Position: Q3 2024 in Review

UBS AM sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 113,386 shares — an estimated $464K sold.

UBS AM first reported a position in ZNTL in Q4 2020 and held it in 15 quarters. The position peaked at $11.6M in Q4 2021. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • UBS AM reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • UBS AM sold 113,386 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $464K.
  • UBS AM first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • UBS AM's Zentalis Pharmaceuticals position peaked at $11.6M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on UBS AM's 13F filing for Q3 2024, filed 14 Nov 2024.